References
- Wang X, Ching YP, Lam WH, Qi Z, Zhang M, Wang JH. Identification of a common protein association region in the neuronal Cdk5 activator. J Biol Chem 2000; 275:31763-9; PMID: 10915792; https://doi.org/10.1074/jbc.M004358200
- Wang J, He X, Luo Y, Yarbrough WG. A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2. Biochem J 2006; 393:489-501; PMID: 16173922; https://doi.org/10.1042/BJ20050960
- Wang J, An H, Mayo MW, Baldwin AS, Yarbrough WG. LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 2007; 12:239-51; PMID: 17785205; https://doi.org/10.1016/j.ccr.2007.07.002
- Wang JB, Wang ZW, Li Y, Huang CQ, Zheng CH, Li P, Xie JW, Lin JX, Lu J, Chen QY, et al. CDK5RAP3 acts as a tumor suppressor in gastric cancer through inhibition of beta-catenin signaling. Cancer Lett 2017; 385:188-97; PMID: 27793695; https://doi.org/10.1016/j.canlet.2016.10.024
- Mak GW, Chan MM, Leong VY, Lee JM, Yau TO, Ng IO, Ching YP. Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res 2011; 71:2949-58; PMID: 21385901; https://doi.org/10.1158/0008-5472.CAN-10-4046
- Zhao JJ, Pan K, Li JJ, Chen YB, Chen JG, Lv L, Wang DD, Pan QZ, Chen MS, Xia JC. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma. PLoS One 2011; 6:e26608; PMID: 22028922; https://doi.org/10.1371/journal.pone.0026608
- Wamsley JJ, Issaeva N, An H, Lu X, Donehower LA, Yarbrough WG. LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro. Cell Cycle 2017; 16(2):213-223; PMID: 28027003; https://doi.org/10.1080/15384101.2016.1261767